Abstract
Background Menopausal vasomotor symptoms (VMS) significantly impact women’s quality of life, and whilst hormone replacement therapy (HRT) is effective, it is not appropriate for all. We aimed to identify new drug targets for VMS and understand reasons for HRT use through genomic analyses.
Methods In up to 153,152 women from UK Biobank, a population-based cohort, we performed a genome-wide association study (GWAS) of VMS derived from linked primary-care records and cross-sectional self-reported data. In a subset of this cohort (n=39,356), we analysed exome-sequencing data to test the association of rare deleterious genetic variants with VMS. Finally, we used Mendelian randomisation analysis to investigate the reasons for HRT use and whether these changed over time.
Findings Our GWAS identified a genetic signal near the gene encoding NK3R (TACR3) associated with a lower risk of VMS (OR=0·85 (95% CI 0·82,0·87) per AT allele, P=1·1×10-26), which was consistent with previous studies. However, rare genetic variants predicted to reduce functional NK3R levels were not associated with VMS (P=0·9), though did delay puberty (P=9×10-11). Younger menopause age was causally-associated with greater HRT use before 2002 but not after.
Interpretation Using genomics we demonstrate that changed HRT use since the early 2000s reflects a switch from preventing post-menopausal complications to primarily treating VMS. We provide support for TACR3 in the genetic basis of VMS but unexpectedly find that rare genomic variants predicted to lower NK3R levels did not modify VMS, despite the proven efficacy of NK3R antagonists, suggesting that further biological understanding could benefit therapeutic efficacy.
Funding Cancer Research UK and UKRI.
Evidence before the study In vivo studies of animal models and clinical studies in humans have determined that menopausal vasomotor symptoms (VMS) result from increased neurokinin B (NKB) signalling via the neurokinin 3 receptor (NK3R) in response to decreased circulating oestradiol levels.
Recent Phase II clinical trials have demonstrated the efficacy of NK3R antagonists in reducing VMS.
A previous GWAS in 17,695 women identified a genetic signal at the TACR3 locus (which codes for NK3R) as associated with VMS. The locus was also genome-wide significant in a GWAS of oestrogen-replacement use (15,305 cases) derived from self-reported medications in UK Biobank.
Added value of this study This study represents a novel approach to analysing the rarely captured phenotype of VMS, since few population-based cohorts have asked about menopausal symptoms.
To the best of our knowledge, this is the first analyses of VMS identified from linked primary care health records. Literature searches of published papers and codelists have not identified any previous studies of VMS in primary care data. The replication of the known GWAS signal for VMS provides a validation of the coding of this phenotype from primary care data.
This is the largest genomic study of VMS currently carried out (92,028 women). Our current analyses are limited by the availability of primary care linked data in ∼45% of the UK Biobank cohort and are based on exome sequencing in 200,000 women. Recently released exome data for the full cohort and further releases of primary care linked data in UK Biobank will allow us to re-visit these analyses further.
Implications of all the available evidence Our analyses of rare coding variation in TACR3 identified an intriguing difference that requires further study; while NK3R antagonist drug treatment reduces VMS, women carrying rare genetic variants resulting in reduced NK3R levels were no less likely to experience VMS.
Our genome-wide analyses replicate the genetic signals for VMS at the TACR3 gene locus, however we were unable to unequivocally identify TACR3 as the causal gene at this locus.
We suggest that the effect of the common genetic variant on reducing VMS may be through as yet uncharacterised regulatory pathways, and that complete inhibition of NK3R signalling is required to eliminate (rather than reduce) VMS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Katherine S. Ruth is supported by Cancer Research UK [grant number C18281/A29019]. Julia K. Prague is supported by the UKRI Expanding Excellence in England award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted using the UK Biobank resource under application number 871. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (REC ref: 21/NW/0157)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in the present study are available on application to UK Biobank.
